Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway
These findings aim to provide insights into the therapeutic potential of targeting EZH2 in combination with immune checkpoint inhibitors for improved treatment of lymphomas.
Authors
- Young‐Woo Jeon (ORCID: https://orcid.org/0000-0003-3362-8200)
- Jung-Yeon Lim (ORCID: https://orcid.org/0000-0001-5903-8810)
- Se Been Kim (ORCID: https://orcid.org/0009-0001-7932-6964)
- Yurim Jeong (ORCID: https://orcid.org/0009-0001-2658-357X)
- Hyewon Jang (ORCID: https://orcid.org/0000-0002-4030-547X)
- Minseo Yu (ORCID: https://orcid.org/0009-0006-3543-6754)
- Wan-Su Choi
- Ryeo Won Kim
Institutions
- Inje University (KR)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1578665
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18